Literature DB >> 12734407

The hepatitis C virus persistence: how to evade the immune system?

Nicole Pavio1, Michael M C Lai.   

Abstract

Hepatitis C virus (HCV) is an emerging virus of medical importance. A majority of HCV infections become chronic and lead to chronic hepatitis, liver cirrhosis and hepatocellular carcinoma. HCV usually induces robust immune responses, but it frequently escapes the immune defense to establish persistent infection. The fact that HCV exists as an evolving quasispecies plays an important role in the selection of escape mutants. Furthermore, several viral proteins interfere with cellular functions, in particular, those involved in the immune response of the host. Several HCV proteins also modulate cell signalling through interaction with different effectors involved in cell proliferation and apoptosis, or in the interferon-signalling pathway. In addition, HCV infects immune cells such as B and T cells, and thus affects their normal functions. These various strategies used by HCV to counter the immune response of the host are reviewed here. A better understanding of these mechanisms would help design new therapeutic targets.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12734407     DOI: 10.1007/bf02970148

Source DB:  PubMed          Journal:  J Biosci        ISSN: 0250-5991            Impact factor:   1.826


  161 in total

1.  Hepatitis C virus core protein binds to the cytoplasmic domain of tumor necrosis factor (TNF) receptor 1 and enhances TNF-induced apoptosis.

Authors:  N Zhu; A Khoshnan; R Schneider; M Matsumoto; G Dennert; C Ware; M M Lai
Journal:  J Virol       Date:  1998-05       Impact factor: 5.103

Review 2.  Infectious transcripts and cDNA clones of RNA viruses.

Authors:  J C Boyer; A L Haenni
Journal:  Virology       Date:  1994-02       Impact factor: 3.616

3.  Detection of a novel unglycosylated form of hepatitis C virus E2 envelope protein that is located in the cytosol and interacts with PKR.

Authors:  Nicole Pavio; Deborah R Taylor; Michael M C Lai
Journal:  J Virol       Date:  2002-02       Impact factor: 5.103

4.  The La antigen binds 5' noncoding region of the hepatitis C virus RNA in the context of the initiator AUG codon and stimulates internal ribosome entry site-mediated translation.

Authors:  N Ali; A Siddiqui
Journal:  Proc Natl Acad Sci U S A       Date:  1997-03-18       Impact factor: 11.205

5.  Hepatic lymphoid aggregates in chronic hepatitis C and mixed cryoglobulinemia.

Authors:  A Monteverde; M Ballarè; S Pileri
Journal:  Springer Semin Immunopathol       Date:  1997

6.  The outcome of acute hepatitis C predicted by the evolution of the viral quasispecies.

Authors:  P Farci; A Shimoda; A Coiana; G Diaz; G Peddis; J C Melpolder; A Strazzera; D Y Chien; S J Munoz; A Balestrieri; R H Purcell; H J Alter
Journal:  Science       Date:  2000-04-14       Impact factor: 47.728

7.  NS5A, a nonstructural protein of hepatitis C virus, binds growth factor receptor-bound protein 2 adaptor protein in a Src homology 3 domain/ligand-dependent manner and perturbs mitogenic signaling.

Authors:  S L Tan; H Nakao; Y He; S Vijaysri; P Neddermann; B L Jacobs; B J Mayer; M G Katze
Journal:  Proc Natl Acad Sci U S A       Date:  1999-05-11       Impact factor: 11.205

8.  Antiapoptotic and oncogenic potentials of hepatitis C virus are linked to interferon resistance by viral repression of the PKR protein kinase.

Authors:  M Gale; B Kwieciszewski; M Dossett; H Nakao; M G Katze
Journal:  J Virol       Date:  1999-08       Impact factor: 5.103

9.  Influence of the genetic heterogeneity of the ISDR and PePHD regions of hepatitis C virus on the response to interferon therapy in chronic hepatitis C.

Authors:  F Puig-Basagoiti; J C Sáiz; X Forns; S Ampurdanès; M Giménez-Barcons; S Franco; A Sánchez-Fueyo; J Costa; J M Sánchez-Tapias; J Rodés
Journal:  J Med Virol       Date:  2001-09       Impact factor: 2.327

10.  Analysis of successful immune responses in persons infected with hepatitis C virus.

Authors:  F Lechner; D K Wong; P R Dunbar; R Chapman; R T Chung; P Dohrenwend; G Robbins; R Phillips; P Klenerman; B D Walker
Journal:  J Exp Med       Date:  2000-05-01       Impact factor: 14.307

View more
  30 in total

1.  Immunopharmacology of CpG oligodeoxynucleotides and ribavirin.

Authors:  Jörg Vollmer; Robert Rankin; Hanna Hartmann; Marion Jurk; Ulrike Samulowitz; Tanja Wader; Andrea Janosch; Christian Schetter; Arthur M Krieg
Journal:  Antimicrob Agents Chemother       Date:  2004-06       Impact factor: 5.191

2.  E sequence analysis of persistently infected mutant Japanese encephalitis virus strains.

Authors:  Qi Li; Keshu Xu; Huafeng Wang; Xia Zhou
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2006

3.  Expression of bcl-2 protein in chronic hepatitis C: effect of interferon alpha 2b with ribavirin therapy.

Authors:  Panasiuk Anatol; Prokopowicz Danuta; Dzieciol Janusz; Panasiuk Bozena
Journal:  World J Gastroenterol       Date:  2005-05-21       Impact factor: 5.742

4.  Hepatitis C Virus E2 Protein Induces Upregulation of IL-8 Pathways and Production of Heat Shock Proteins in Human Thyroid Cells.

Authors:  Sara Salehi Hammerstad; Mihaela Stefan; Jason Blackard; Randall P Owen; Hanna J Lee; Erlinda Concepcion; Zhengzi Yi; Weijia Zhang; Yaron Tomer
Journal:  J Clin Endocrinol Metab       Date:  2017-02-01       Impact factor: 5.958

Review 5.  Hepatitis C virus infection and apoptosis.

Authors:  Richard Fischer; Thomas Baumert; Hubert-E Blum
Journal:  World J Gastroenterol       Date:  2007-09-28       Impact factor: 5.742

6.  Selection of cyclic peptide aptamers to HCV IRES RNA using mRNA display.

Authors:  Alexander Litovchick; Jack W Szostak
Journal:  Proc Natl Acad Sci U S A       Date:  2008-09-29       Impact factor: 11.205

Review 7.  Production and pathogenicity of hepatitis C virus core gene products.

Authors:  Hui-Chun Li; Hsin-Chieh Ma; Chee-Hing Yang; Shih-Yen Lo
Journal:  World J Gastroenterol       Date:  2014-06-21       Impact factor: 5.742

8.  Effect of killer immunoglobulin-like receptors in the response to combined treatment in patients with chronic hepatitis C virus infection.

Authors:  J R Vidal-Castiñeira; A López-Vázquez; R Díaz-Peña; R Alonso-Arias; J Martínez-Borra; R Pérez; J Fernández-Suárez; S Melón; J Prieto; L Rodrigo; C López-Larrea
Journal:  J Virol       Date:  2010-01       Impact factor: 5.103

Review 9.  The interferon inducing pathways and the hepatitis C virus.

Authors:  Eliane F Meurs; Adrien Breiman
Journal:  World J Gastroenterol       Date:  2007-05-07       Impact factor: 5.742

10.  Pretreatment sequence diversity differences in the full-length hepatitis C virus open reading frame correlate with early response to therapy.

Authors:  Maureen J Donlin; Nathan A Cannon; Ermei Yao; Jia Li; Abdus Wahed; Milton W Taylor; Steven H Belle; Adrian M Di Bisceglie; Rajeev Aurora; John E Tavis
Journal:  J Virol       Date:  2007-05-23       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.